Kura Oncology Inc KURA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Kura Oncology to Participate in Two Investor Conferences in November
Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026
Kura Oncology to Report Third Quarter Financial Results on November 10
Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes
Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $7.43
- Day Range
- $7.30–7.82
- 52-Week Range
- $6.75–13.90
- Bid/Ask
- $7.67 / $7.77
- Shares Outstanding
- 91.88M
- Market Cap
- $713.90M
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.70
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 260
- Website
- https://www.kuraoncology.com
Valuation
Metric | KURA |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 39.75 |
Price/Sales | 8.70 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | KURA |
|---|---|
Quick Ratio | 3.41 |
Current Ratio | 3.60 |
Interest Coverage | −227.12 |
Quick Ratio
KURA
Profitability
Metric | KURA |
|---|---|
Return on Assets (Normalized) | −45.19% |
Return on Equity (Normalized) | −244.30% |
Return on Invested Capital (Normalized) | −215.18% |
Return on Assets
KURA
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|bBzL#B | LOCK|GpH<$ | $137B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|#!@jjV | LOCK|<Zk> | $99B | |||
| Moderna Inc MRNA | LOCK|>fj?L?f | LOCK|Dc< | $90B | |||
| argenx SE ADR ARGX | LOCK|PxTx$^ | LOCK|$q | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|p#>&?D> | LOCK|>>d | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|<>#Pq!X | LOCK|pvZc> | $31B | |||
| Incyte Corp INCY | LOCK|WWRq<m% | LOCK|!> | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|>&z?#? | LOCK|bP@# | $22B | |||
| BioNTech SE ADR BNTX | LOCK|>W?lXD | LOCK|$g | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|N>cZ@H | LOCK|#V? | $16B |
United States